

Amendments to the Specification:

At Published Application No. 20020198511, [0028]-[0029] in BRIEF DESCRIPTION OF THE DRAWINGS, please amend as follows:

FIG. 3A is a schematic view of the device of FIG. 2 following puncture of the sclera of the eye by the piercing member of the device; and

FIG. 3B 4 is a schematic view of the device of FIG. 2/3A following piercing of the retina by the cannula of the device.

FIG. 4A is a schematic view of the device of FIG. 2/3A depicting use of the device to treat multiple treatment sites by varying the angle of the portion of the device that lies outside of the eye.

FIG. 4B is a schematic view of the device of FIG. 2/4A following piercing of the retina by the cannula of the device.

At Published Application No. 20020198511, [0060]-[0061], please amend as follows:

[0060] The devices of FIGS. 1 and 2 are used to treat one or more target/treatment sites, each of which is generally located within an eye. Although the description of FIGS. 3A-B and 4A-B below refer to use of the device of FIG. 2, these descriptions also are applicable to use of the device of FIG. 1. Also, all common elements of the devices 10, 10' of FIGS. 1 and 2 will be referred to in these descriptions by their FIG. 2 reference numbers.

[0061] Referring now to FIG. 3A, in preparation for its use, the device 10' gains access to the vitreous humor 102 of a human eye 100. This occurs by placing enough pressure onto the device 10' such that the sharp distal end 18' of the piercing member 12' penetrates the sclera 104 of the eye 100, thus creating a continuous passageway (not shown) between the device and the vitreous humor 102 of the eye 100.

At Published Application No. 20020198511, [0064], please amend as follows:

[0064] Once a passageway into the eye 100 is created as such, the cannula 44' and attached tubing 32' (or, in the case of the device 10 of FIG. 1, the rigid member 26 with attached cannula 44 positioned therewithin) is advanced into and through the device 10' and to a treatment/target site. In FIGS. 3B and 4B, the target site is the retina 110 of the eye 100, but it is understood that the target site may be any portion of the eye.

At Published Application No. 20020198511, [0082], please amend as follows:

[0082] Another advantage of a device 10' of the present invention is that an operator may use it to treat multiple treatment sites simply by varying the angle of the portion of the device that lies outside of the eye 100, for example, as depicted in Figs. 3A-4B, thus avoiding the need for creation of multiple entry sites. Even in the event, however, that multiple entry sites were required, each entry site would be self-sealing as described above.